(Q43870660)

27 November 2017

title

Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy (English)

1 reference

27 November 2017

2

1 reference

27 November 2017

4

Toshihiko Doi

1 reference

27 November 2017

5

Atsushi Ohtsu

1 reference

27 November 2017

Kohei Shitara

1

1 reference

27 November 2017

Kei Muro

series ordinal

3

1 reference

27 November 2017

publication date

25 May 2013

1 reference

Journal of Cancer Research and Clinical Oncology

27 November 2017

published in

1 reference

27 November 2017

volume

139

1 reference

27 November 2017

issue

8

1 reference

27 November 2017

page(s)

1383-1389

1 reference

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Progression-free survival is a surrogate for survival in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Bootstrap Methods: Another Look at the Jackknife

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1452-Y

Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23708301

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00432-013-1452-Y

1 reference

27 November 2017

1 reference